momelotinib momelotinib momelotinib (inn, formerly gs-0387, cyt-387) is an inhibitor of janus kinases jak1 and jak2, acting as an atp competitor with ic50 values of 11 and 18 nm, respectively. the inhibitor is significantly less active towards other kinases, including jak3 (ic50 = 0.16 μm). momelotinib names preferred iupac name n-(cyanomethyl)-4-benzamide other names cyt-387, cyt-11387, gs-0387 identifiers cas number 1056634-68-4 3d model (jsmol) interactive image chebi chebi:91407 chemspider 24676202 iuphar/bps 7791 kegg d10315 pubchem cid 25062766 unii 6o01gms00p y inchi inchi=1s/c23h22n6o2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11h,12-16h2,(h,25,30)(h,26,27,28)key: zvhndzwqtbevry-uhfffaoysa-n smiles c1cc(ccc1c2ccnc(n2)nc3ccc(cc3)n4ccocc4)c(=o)ncc#n properties chemical formula c23h22n6o2 molar mass 414.469 g·mol−1 pharmacology atc code none except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references as of 2011, momelotinib is being developed as a drug for myelofibrosis and currently undergoes phase i/ii clinical trials. additional potential treatment indications for momelotinib include other myeloproliferative neoplasms, cancer (solid and liquid tumors) and inflammatory conditions. as of 2016, momelotinib is being investigated for primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-pv/et mf), as well as a treatment for relapsed or refractory metastatic pancreatic ductal adenocarcinoma (in combination with capecitabine and oxaliplatin). discovery the drug was originally discovered by australian drug discovery company cytopia, then developed by ym biosciences inc. (since acquired by gilead sciences as of 2013).